Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy.

Published

Journal Article

Despite salvage radiation therapy (SRT) for recurrent prostate cancer (PCa) after radical prostatectomy (RP), some patients still progress to metastases. Identifying these men would allow them to undergo systemic therapy including testing novel therapies to reduce metastases risk.To test whether the genomic classifier (GC) predicts development of metastatic disease.Retrospective multi-center and multi-ethnic cohort study from two academic centers and one Veterans Affairs Medical Center in the United States involving 170 men receiving SRT for recurrent PCa post-RP.Time from SRT to development of metastatic disease tested using Cox regression, survival c-index, and decision curve analysis. Performance of GC was compared to the Cancer of the Prostate Risk Assessment Score and Briganti risk models based on these metrics.With a median 5.7 yr follow-up after SRT, 20 patients (12%) developed metastases. On multivariable analysis, for each 0.1 unit increase in GC (scaled from 0 to 1), the hazard ratio for metastasis was 1.58 (95% confidence interval 1.16-2.17; p=0.002). Adjusting for androgen deprivation therapy did not materially change the results. The c-index for GC was 0.85 (95% confidence interval 0.73-0.88) versus 0.63-0.65 for published clinico-pathologic risk models. The 5-yr cumulative incidence of metastasis post-SRT in patients with low, intermediate, and high GC scores was 2.7%, 8.4%, and 33.1%, respectively (p<0.001).While validation in larger, prospectively collected cohorts is required, these data suggest GC is a strong predictor of metastases among men receiving SRT for recurrent PCa post-RP, accurately identifying men who are excellent candidates for systemic therapy due to their very high-risk of metastases.Genomic classifier and two clinico-pathologic risk models were evaluated on their ability to predict metastases among men receiving salvage radiation therapy for recurrent prostate cancer. Genomic classifier was able to identify candidates for further therapies due to their very high-risk of metastases.

Full Text

Duke Authors

Cited Authors

  • Freedland, SJ; Choeurng, V; Howard, L; De Hoedt, A; du Plessis, M; Yousefi, K; Lam, LL; Buerki, C; Ra, S; Robbins, B; Trabulsi, EJ; Shah, NL; Abdollah, F; Feng, FY; Davicioni, E; Dicker, AP; Karnes, RJ; Den, RB

Published Date

  • October 2016

Published In

Volume / Issue

  • 70 / 4

Start / End Page

  • 588 - 596

PubMed ID

  • 26806658

Pubmed Central ID

  • 26806658

Electronic International Standard Serial Number (EISSN)

  • 1873-7560

International Standard Serial Number (ISSN)

  • 0302-2838

Digital Object Identifier (DOI)

  • 10.1016/j.eururo.2016.01.008

Language

  • eng